Cidala Patient Program

In September 2020, Kos designed, developed, and implemented the Cidala Patient Program. Arrotex Pharmaceuticals (Arrotex) partnered with PharmaPrograms to promote the Cidala Patient Program through community pharmacies. The Cidala Patient Program (Program) supports patients prescribed Tadalafil and dispensed as Cidala (tadalafil) tablets.

The Program aims to improve medication compliance and adherence, by facilitating communication between pharmacists and patients. This is a private prescription-only medicine used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate).

Entocort® Patient Program

In August 2020, Kos designed, developed, and implemented the Entocort® Patient Program through community pharmacies. The Entocort® Program (Program) supports patients prescribed Entocort® (budesonide controlled release) capsules, which is a private prescription-only medicine indicated for the induction of remission in adult patients with mild to moderate Crohn’s disease.

Juno PC Pharmacy Program

In June 2020, Kos designed, developed, and implemented the Juno PC Pharmacy Program through community pharmacies. This pharmacist lead program supports patients that are dispensed PHENTERMINE JUNO ER (phentermine) extended release tablets, and aims to improve medication
compliance and adherence, by facilitating communication between pharmacists and patients.

Domion® (Agomelatine) Pharmacy Program

In May 2020, Kos designed, developed, and implemented the Domion Patient Program (Program) which supports patients prescribed Domion (agomelatine) tablets.

This pharmacist-led Program aims to improve medication compliance and adherence, by facilitating regular communication between pharmacists and patients.

Valdoxan Patient Program

In November 2019, Kos designed, developed, and implemented the Valdoxan Patient Program with Servier Laboratories (Aust) Pty Ltd). Servier has partnered with PharmaPrograms to provide the Program which supports patients prescribed Valdoxan (agomelatine) tablets. This medication is a private prescription-only medicine used to treat depression in adults including to prevent relapse.

Amgen Pharmacy Partnership in Osteoporosis INTervention (APPOINT) Program

In March 2019, Kos designed, developed, and implemented the Amgen Pharmacy Partnership in Osteoporosis INTervention (APPOINT) Program. Recognising the critical role that pharmacy plays in identifying and treating osteoporosis Amgen Australia has joined with PharmaPrograms to create the Program with the aim of supporting pharmacies to reduce osteoporotic fractures.

Teva Wake Patient Programs

In August 2018 Kos designed, developed, and implemented the Modafinil Patient Screening Program (Modafinil Program) and the Nuvigil® Patient Program (Nuvigil® Program) for Teva Pharma Australia Pty. Ltd. (Teva). It partnered with PharmaPrograms to facilitate the Program through community pharmacies. Modafinil and Nuvigil® (armodafinil) are both listed on the Pharmaceutical Benefits Scheme (PBS). Modafinil and Nuvigil® are two wakefulness-promoting agents for oral administration.

Teva DuoResp® Spiromax® New-to-Therapy Patient Program

In July 2018, Kos designed, developed, and implemented the Teva DuoResp® Spiromax® New-to-Therapy Patient Program (Program) for Teva Pharma Australia Pty. Ltd. (Teva). The program partnered with Community Pharmacy to provide DuoResp Spiromax (budesonide/formoterol) is an inhaled medicine used to treat asthma and chronic obstructive pulmonary disease (COPD).

Astellas Urology Patient Program

In June 2018, Kos designed, developed, and implemented the Astellas Urology Patient Program through community pharmacies. The program was supported by Astellas Pharma Australia Pty. Ltd. in partnership with PharmaPrograms. Patients prescribed Betmiga® (mirabegron) and Vesicare® (solifenacin succinate) are able to participate in this Astellas Urology Patient Program.

Astellas Advagraf® XL Patient Program

In April 2018, Kos designed, developed, and implemented the Advagraf® XL Patient Program with Astellas Pharma Australia Pty. Ltd. and in partnership with PharmaPrograms. Advagraf® XL is a once-daily prolonged-release tacrolimus, an immunosuppressive agent indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.